A New Approach to Detect Cancer Using Luminescent Nanoparticles

Early detection of cancer remains a major challenge in improving recovery chances and reducing mortality. Among the avenues being explored, researchers are closely examining telomerase, an enzyme often present in excess in cancer cells. This protein plays a key role in cell division, and its abnormally high levels can signal the presence of cancer long before the first symptoms appear. However, current methods for measuring this biological marker are sometimes costly, time-consuming, or imprecise.

A team of scientists has developed an innovative approach using silica nanoparticles doped with europium, a rare element with unique luminescent properties. These nanoparticles, approximately 120 nanometers in size, are coated with antibodies capable of specifically recognizing telomerase. When they come into contact with this enzyme, they emit visible light, allowing its presence in a sample to be quantified. Unlike conventional dyes, these nanoparticles provide more stable and easier-to-detect light, even in small quantities.

To create these nanoparticles, the researchers first incorporated europium into a silica structure, a biocompatible and durable material. They then modified the surface to attach antibodies, ensuring targeted recognition of telomerase. Tests conducted on human cancer cells, such as those from breast or cervical cancer, showed that these nanoparticles produce a clear and measurable light signal. This signal is much sharper than that obtained with traditional dyes, making analysis easier.

The advantage of this technique lies in its simplicity and reliability. The nanoparticles retain their luminosity longer and are more resistant to biological interference, making them suitable for laboratory use. Initial results indicate that they can detect variations in telomerase concentration in cell extracts, paving the way for faster and less expensive analyses.

This method does not directly measure the enzymatic activity of telomerase but rather its total quantity in a sample. Although further testing on biological fluids or human tissues is needed to validate its clinical use, this advancement represents a promising step. In the long term, it could enable more accessible and effective screening for various types of cancer, complementing existing tools.

Luminescent nanoparticles could thus become a valuable tool for researchers and physicians, offering a more efficient alternative to current techniques. Their development illustrates how nanotechnology and materials chemistry can contribute to improving early diagnosis—a key factor in the fight against cancer.

Content References

Official Reference

DOI: https://doi.org/10.1007/s11051-026-06620-2

Title: Potentially a new approach in cancer diagnosis: development of lanthanide-loaded nanoparticle-based biosensors for determining telomerase levels

Journal: Journal of Nanoparticle Research

Publisher: Springer Science and Business Media LLC

Authors: Mesut Kaplan; Lokman Uzun